Printer Friendly

CEPHALON BEGINS MODAFINIL CLINICAL TRIAL IN UNITED STATES; EXPANDS MARKETING TERRITORY TO U.K. AND IRELAND

 WEST CHESTER, Pa., Aug. 17 /PRNewswire/ -- Cephalon, Inc. (NASDAQ: CEPH) announced today the initiation of U.S. clinical trials of modafinil for the treatment of narcolepsy as well as the expansion of its marketing territory for modafinil to include the United Kingdom and Ireland.
 Cephalon is initiating the U.S. studies in healthy volunteers to support dose selection for pivotal efficacy trials. Phase III pivotal studies in patients with narcolepsy are planned to begin at leading U.S. sleep centers following the completion of the current study.
 In January 1993, Cephalon licensed modafinil from Laboratoire L. Lafon of Paris for development in the United States and Mexico. Under a recent amendment to that agreement, Cephalon now has the exclusive right to market mondafinil in the United Kingdom and Ireland upon approval in those countries.
 "We are pleased to begin the clinical development program for modafinil on schedule," said Cephalon President and CEO Frank Baldino Jr., Ph.D. "The expansion of our territory for modafinil into the United Kingdom and Ireland represents an important potential market opportunity for the company and underscores our intent to develop products around the globe."
 Modafinil is a synthetic compound developed by Lafon that acts selectively on the alpha adrenergic system in the brain. Researchers believe this system is involved with narcolepsy, a debilitating sleep disorder that affects more than 125,000 people in the United States. In 1992 Lafon received regulatory approval for modafinil in France, and expects to seek regulatory approval of modafinil in other European countries later this year.
 Narcolepsy is generally characterized by an uncontrollable propensity to fall asleep and has no known cure. Current therapies that treat disease symptoms, such as amphetamine-type stimulants, may be addictive or have other side effects. If approved, modafinil would be the first new product in the United States to address this disorder in many years.
 Founded in 1951, Lafon is a privately owned, research-based, mid- size ethical pharmaceutical company located in France. Lafon research specializes in discovery and development of innovative compounds, especially in CNS and cardiovascular therapies.
 Cephalon is a leader in the discovery and development of products to treat neurological diseases and disorders. The company's principal focus is on neurodegenerative diseases such as amyotrophic lateral sclerosis (Lou Gehrig's disease), peripheral neuropathy, Alzheimer's disease, head and spinal cord injury, and stroke.
 /delval/
 -0- 8/17/93
 /CONTACT: Jason Rubin or Lyn Hyduke of Cephalon, 215-344-0200; or Karen Bergman of Burns McClellan, 212-505-1919, for Cephalon; or Bill Mattson for Laboratoire L. Lafon, 314-469-7600/


CO: Cephalon, Inc.; Laboratoire L. Lafon ST: Pennsylvania IN: MTC SU:

MJ-CC -- PH001 -- 3378 08/17/93 08:02 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Aug 17, 1993
Words:438
Previous Article:REGIS SALONS UNVEIL LOOKS FOR FALL/WINTER
Next Article:WORLDSPAN SIGNS $50 MILLION AGREEMENT WITH AT&T
Topics:

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters